Abstract: Described is a method for preparing an Immunoglobulin G (IgG) enriched fraction from a C1-INH depleted plasma supernatant. Isolation of Immunoglobulin G (IgG) enriched fraction from a C1-INH depleted plasma supernatant provided an alternative starting material for the manufacturing process. In the present invention, C1-INH depleted plasma supernatant is treated with heparin before further processing.

Abstract: Provided herein are nanoparticles complexed with binding agents and/or therapeutic agents (e.g., antibody-complexed albumin-bound paclitaxel/doxorubicin nanoparticles and antibody-complexed albumin-bound paclitaxel/SN38 nanoparticles) and pharmaceutical compositions thereof. Additionally, provided herein are methods of making nanoparticles complexed with binding agents and/or therapeutic agents (e.g., antibody-complexed albumin-bound paclitaxel/doxorubicin nanoparticles and antibody-complexed albumin-bound paclitaxel/SN38 nanoparticles) and methods of treating cancer in a patient in need thereof.

Abstract: The present disclosure provides a composition comprising Bifidobacterium lactis and human milk oligosaccharides (HMOs) and use thereof. The composition is capable of effectively enhancing resistance of an organism to Staphylococcus aureus infection, improving innate immunity of an organism, and/or anti-aging, and can be added to various health foods and healthcare foods.

Abstract: Chronic inflammatory bowel disorders (IBDs) are characterized by altered intestinal permeability, prompting inflammatory, oxidative stress and immunological factors. Gut microbiota disorders impact brain function via the bidirectional gut-brain axis, influencing behavior through inflammatory cascades, oxidative stress, and neurotransmitter levels. The present invention comprises lyophilized milk kefir alone and lyophilized milk kefir as solid carriers loaded with self-nanoemulsifying self-nanosuspension (SNESNS) of licorice extract. Daily administration of lyophilized milk kefir loaded with SNESNS restores normal body weight and intestinal mucosa while significantly reducing submucosal inflammatory cell infiltration, leading to significant alleviation of neurotransmitter levels and improved memory functions, thereby addressing gut-brain axis disorders. Additionally, it normalized fecal microbiome constituents, inflammatory cytokine levels, and oxidative stress in examined tissues and serum.

Abstract: The current disclosure provides methods and compositions for treating autoimmune conditions, including allergic conditions such as food allergy. Certain aspects of the disclosure relate to methods for treatment of food allergy comprising administering a composition comprising Phascolarctobacterium faecium and/or Ruminococcus bromii. In some aspects, disclosed are compositions comprising isolated, lyophilized bacteria such as Phascolarctobacterium faecium and/or Ruminococcus bromii.

Abstract: This invention relates to methods for selecting a treatment, treating, and predicting survival time in subjects with cancer, such as colorectal cancer, based on tumor expression levels of chemokines, cytotoxic genes, and/or dendritic cell genes.

Abstract: Chemical-free, biological insecticide formulation for the control of insect pests in plants, wherein said formulation comprises Bacillus subtilis strain No. 5 NRRL 50391, at defined concentrations, palatability enhancers or attractants, a carrier selected from clays, kaolin, tale, zeolite, water, vegetable oils, paraffinic or non-paraffinic minerals among other agents.

Abstract: The present invention relates to the technical field of microorganisms, in particular to a Bifidobacterium animalis subsp. lactis ATM-209 (GOLDGUT-BB18) inhibiting Helicobacter Pylori and an application thereof. The Bifidobacterium animalis subsp. lactis ATM-209 (GOLDGUT-BB18) provided by the present invention is preserved in China General Microbiological Culture Collection Center of China Committee for Culture Collection of Microorganisms, with a preservation number of CGMCC No. 25896. The strain has good acid tolerance, and can well adapt to a gastric environment; the strain has an obvious effect for inhibiting the growth of Helicobacter Pylori, can inhibit the in-vivo colonization of the Helicobacter Pylori in an animal experiment and relieve the inflammation caused by Helicobacter Pylori infection, and has broad application prospects in clinical prevention, treatment and inhibition of diseases related to Helicobacter pylori infection and gastrointestinal health food.

Abstract: The present invention relates to a method for purification of botulinum toxin with improved purification purity and yield. When the method for purification of botulinum toxin of the present invention is used, botulinum toxin can be purified with a very high yield.

Abstract: A problem to be solved by the present invention is to provide a composition (1) for inhibiting differentiation of osteoclast precursor cells into osteoclasts, improving bone metabolism, and/or inhibiting bone density reduction, the composition (1) including a culture supernatant or a processed product thereof, the culture supernatant being obtainable by culturing immune cells in the presence of lactic acid bacteria or a processed product thereof, or a composition (2) for inhibiting differentiation of osteoclast precursor cells into osteoclasts, improving bone metabolism, and/or inhibiting bone density reduction, the composition (2) including Lactobacillus plantarum strain L-137 (Lactobacillus plantarum L-137) or a processed product thereof. These compositions solve the problem.

Abstract: Provided herein is a medical infusion pump system that contains a pump and a reservoir containing an aqueous liquid pharmaceutical composition that is delivered to a subject by the pump and that contains an insulin compound at a concentration of 400 U/mL or more, ionic zinc and a non-ionic surfactant, and wherein the pump delivers the composition in pulses wherein the volume of the pulse is 0.5 ?L or less.

Abstract: Provided are a microorganism in which activity of a GNAT family N-acetyltransferase protein is weakened; a method for producing O-acetyl homoserine and L-methionine using the same; a composition for producing O-acetyl homoserine, the composition including the microorganism; and use of the microorganism for producing O-acetyl homoserine or L-methionine.

Abstract: The present invention generally relates to pharmacokinetic and pharmacodynamics markers for cancer therapeutic regimens and methods of treating cancer. Oncolytic virus probes that comprise a nucleic acid encoding soluble interferon beta (IFN?) and methods for use thereof are provided.

Abstract: Provided herein, are methods and compositions for detecting heteromeric protein complexes in biological samples. The methods and compositions allow for capturing and detecting the protein complex with substantially the same antibody, while avoiding detection of native proteins.

Abstract: The present invention relates to an extract of bacteria of the genus Sphingomonas, and compositions comprising an extract of bacteria of the genus Sphingomonas or at least one bacterium of the genus Sphingomonas for use in the prevention and/or the treatment of cutaneous reactions caused by an allergic reaction and for use in the modulation of the immune response and optionally in the reinforcement of the barrier function of the skin.

Abstract: The present invention is applied to the field of Biotechnology and Immunology and refers to combinations of immunogenic peptides, chimeric peptides, compositions that comprise them and the uses thereof for control of ticks, particularly ticks of the species Rhipicephalus microplus. The present invention further provides kits containing the combinations, chimeric peptides and/or compositions comprising the combinations of immunogenic peptides, and a method for inducing immune response in animals, particularly bovines.

Abstract: In one aspect the present invention is directed to mutant Neutrophil gelatinase-associated lipocalin (NGAL) proteins that have the ability to bind to siderophores, such as enterochelin, and to chelate and transport iron, and that are excreted in the urine. Such NGAL mutants, and complexes thereof with siderophores, can be used to clear excess iron from the body, for example in the treatment of iron overload. The NGAL mutants of the invention also have antibacterial activity and can be used in the treatment of bacterial infections, such as those of the urinary tract.

Abstract: The disclosure relates to a genetically engineered Z. mobilis ZM4 for producing PHB and uses thereof. A variety of strains capable of producing both PHB and ethanol that are constructed by integrating three codon-optimized essential genes for exogenous PUB biosynthesis, phaA, phaB and phaC, together with a tetracycline-inducible promoter Ptet into the genome of ZM4.

Abstract: An application of polyethylene glycol (PEG)-interferon and a protooncogene product targeting inhibitor in synergistic inhibition of tumors. Specifically, provided is use of an active ingredient combination. The active ingredient combination comprises PEG-interferon and a protooncogene product targeting inhibitor, and the combination is used for preparing a pharmaceutical composition for synergistic treatment of tumors. The active ingredient combination can synergistically inhibit the growth of tumors (especially lung, stomach, breast and liver cancers) effectively, and can significantly reduce toxic and side effects, and therefore can be widely used in targeted therapy of the tumors.

Abstract: A composition that includes tahina and probiotic bacteriais can be formulated for oral administration. The composition can also include at least one polyphenol originating in a plant other than sesame. The composition can be used in treatment of a neurodegenerative disease or disorder, such as Alzheimer's disease. A method for the preparation of the composition includes intimately mixing the tahina and the probiotic bacteria, while homogenizing without damaging the probiotic bacteria. The composition can be encapsulated within a pH-dependent enteric-coating polymer capable of protecting the mixture from gastric (stomach) acidity.